Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis

Status Recruiting

Clinical Trial Summary

Echinococcosis is a severe parasitosis caused by the development of the tapeworm larva Echinococcus multilocularis, responsible for alveolar echinococcosis (AE) or Echinococcus granulosus, responsible for cystic echinococcosis (CE). The treatment is based on surgery (only possible in 30 to 40% of cases) and/or on a benzimidazole antiparasitic treatment, especially albendazole. Albendazole is only parasitostatic, it slows down the development of the parasite but does not kill it. It is often prescribed for life. Monitoring the effectiveness of the treatment is therefore necessary, requiring radiological and serological monitoring once or twice a year. Being a chronic disease whose treatment is not always curative, patients quality of life is impacted, with a high level of anxiety described in some patients. The diagnosis, evoked on radiological arguments, is then confirmed by serological techniques, whose sensitivity for EA diagnosis is good (95%) in the absence of immunosuppression (now observed in 25% of EA patients). Sensitivity is lower for CE diagnosis (70% or even less than 50% in certain clinical forms). Quantitative real-time PCR (QPCR) techniques on blood samples are now used in many infectious pathologies to quantify the circulating DNA load, and improve diagnosis and therapeutic monitoring. The presence of circulating parasitic DNA has been reported in both types of echinococcosis. A new Echinococcus spp.multiplex QPCR technique (QPCR-Echino) allowing the detection of DNA from E. multilocularis and different species of the E. granulosus complex of European occurrence, in different types of biological samples, has recently been developed in the French National Reference Center for Echinococcosis laboratory. The investigators wish to evaluate QPCR-Echino for the detection of DNA in tissues, as well as in blood, for the diagnosis of Echinococcosis. This technique could improve the sensitivity of biological diagnosis, especially in immunocompromised patients, who often experience significant diagnostic delays, and could also provide information on the virulence and viability of the strains involved.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05824442
Study type	Interventional
Source	Centre Hospitalier Universitaire de Besancon
Contact	Laurence MILLON, PharmD, PhD
Phone	0370632353
Email	lmillon@chu-besancon.fr
Status	Recruiting
Phase	N/A
Start date	October 24, 2023
Completion date	October 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05845112` - Start Taking Action For TB Diagnosis
Not yet recruiting	`NCT05889312` - Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Completed	`NCT01194557` - Introducing Rapid Diagnostic Tests Into the Private Health Sector	N/A
Completed	`NCT04257955` - COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
Recruiting	`NCT05698212` - Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers	Phase 2
Recruiting	`NCT03372330` - Peripheral Artery Disease and Sepsis Outcomes	N/A
Active, not recruiting	`NCT06134011` - A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Recruiting	`NCT06289803` - The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Not yet recruiting	`NCT05464576` - Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis	N/A
Completed	`NCT06185127` - Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy	Phase 3
Not yet recruiting	`NCT06463223` - HIBOC = Hepatic Imaging Biomarkers in Obese Children
Not yet recruiting	`NCT06072820` - Analytical Evaluation of the Endotest® Diagnostic	N/A
Recruiting	`NCT05587114` - Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
Recruiting	`NCT06230458` - Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma	N/A
Not yet recruiting	`NCT05948410` - How Does the Mood of the Patients Change Before and After the Invasive Urodynamic Study?
Not yet recruiting	`NCT05947565` - Patient Position and Invasive Urodynamic Study Results in Males	N/A
Not yet recruiting	`NCT04490746` - Identifcation of Biomarkers for Active Pulmonary Tuberculosis
Completed	`NCT03381131` - Chinese Version of Fibromyalgia Criteria and Severity Scales Study
Recruiting	`NCT05992519` - Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis — HIS-QPCR-ECH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms